279 related articles for article (PubMed ID: 30170989)
1. Overexpression of Periostin in Tumor Biopsy Samples Is Associated With Prostate Cancer Phenotype and Clinical Outcome.
Cattrini C; Rubagotti A; Nuzzo PV; Zinoli L; Salvi S; Boccardo S; Perachino M; Cerbone L; Vallome G; Latocca MM; Zanardi E; Boccardo F
Clin Genitourin Cancer; 2018 Dec; 16(6):e1257-e1265. PubMed ID: 30170989
[TBL] [Abstract][Full Text] [Related]
2. The Role of Prostate-specific Antigen Persistence After Radical Prostatectomy for the Prediction of Clinical Progression and Cancer-specific Mortality in Node-positive Prostate Cancer Patients.
Bianchi L; Nini A; Bianchi M; Gandaglia G; Fossati N; Suardi N; Moschini M; Dell'Oglio P; Schiavina R; Montorsi F; Briganti A
Eur Urol; 2016 Jun; 69(6):1142-8. PubMed ID: 26749093
[TBL] [Abstract][Full Text] [Related]
3. Predictors of biochemical recurrence after Retzius-sparing robot-assisted radical prostatectomy: Analysis of 359 cases with a median follow-up period of 26 months.
Abdel Raheem A; Chang KD; Alenzi MJ; Ham WS; Han WK; Choi YD; Rha KH
Int J Urol; 2018 Dec; 25(12):1006-1014. PubMed ID: 30276864
[TBL] [Abstract][Full Text] [Related]
4. Increased mediator complex subunit CDK19 expression associates with aggressive prostate cancer.
Becker F; Joerg V; Hupe MC; Roth D; Krupar R; Lubczyk V; Kuefer R; Sailer V; Duensing S; Kirfel J; Merseburger AS; Brägelmann J; Perner S; Offermann A
Int J Cancer; 2020 Jan; 146(2):577-588. PubMed ID: 31271443
[TBL] [Abstract][Full Text] [Related]
5. Prognostic value of stromal and epithelial periostin expression in human prostate cancer: correlation with clinical pathological features and the risk of biochemical relapse or death.
Nuzzo PV; Rubagotti A; Zinoli L; Ricci F; Salvi S; Boccardo S; Boccardo F
BMC Cancer; 2012 Dec; 12():625. PubMed ID: 23273263
[TBL] [Abstract][Full Text] [Related]
6. Impact of positive surgical margins on prostate-specific antigen failure after radical prostatectomy in adjuvant treatment-naïve patients.
Ploussard G; Agamy MA; Alenda O; Allory Y; Mouracade P; Vordos D; Hoznek A; Abbou CC; de la Taille A; Salomon L
BJU Int; 2011 Jun; 107(11):1748-54. PubMed ID: 20883488
[TBL] [Abstract][Full Text] [Related]
7. Single Positive Lymph Node Prostate Cancer Can Be Treated Surgically without Recurrence.
Kim DK; Koo KC; Abdel Raheem A; Kim KH; Chung BH; Choi YD; Rha KH
PLoS One; 2016; 11(3):e0152391. PubMed ID: 27031340
[TBL] [Abstract][Full Text] [Related]
8. Prostate extracellular vesicles in patient plasma as a liquid biopsy platform for prostate cancer using nanoscale flow cytometry.
Biggs CN; Siddiqui KM; Al-Zahrani AA; Pardhan S; Brett SI; Guo QQ; Yang J; Wolf P; Power NE; Durfee PN; MacMillan CD; Townson JL; Brinker JC; Fleshner NE; Izawa JI; Chambers AF; Chin JL; Leong HS
Oncotarget; 2016 Feb; 7(8):8839-49. PubMed ID: 26814433
[TBL] [Abstract][Full Text] [Related]
9. Improved risk stratification for biochemical recurrence after radical prostatectomy using a novel risk group system based on prostate specific antigen density and biopsy Gleason score.
Freedland SJ; Wieder JA; Jack GS; Dorey F; deKernion JB; Aronson WJ
J Urol; 2002 Jul; 168(1):110-5. PubMed ID: 12050502
[TBL] [Abstract][Full Text] [Related]
10. Prostate cancer Ki-67 (MIB-1) expression, perineural invasion, and gleason score as biopsy-based predictors of prostate cancer mortality: the Mayo model.
Tollefson MK; Karnes RJ; Kwon ED; Lohse CM; Rangel LJ; Mynderse LA; Cheville JC; Sebo TJ
Mayo Clin Proc; 2014 Mar; 89(3):308-18. PubMed ID: 24486077
[TBL] [Abstract][Full Text] [Related]
11. Prognostic utility of biopsy-derived cell cycle progression score in patients with National Comprehensive Cancer Network low-risk prostate cancer undergoing radical prostatectomy: implications for treatment guidance.
Tosoian JJ; Chappidi MR; Bishoff JT; Freedland SJ; Reid J; Brawer M; Stone S; Schlomm T; Ross AE
BJU Int; 2017 Dec; 120(6):808-814. PubMed ID: 28481440
[TBL] [Abstract][Full Text] [Related]
12. High immunoexpression of Ki67, EZH2, and SMYD3 in diagnostic prostate biopsies independently predicts outcome in patients with prostate cancer.
Lobo J; Rodrigues Â; Antunes L; Graça I; Ramalho-Carvalho J; Vieira FQ; Martins AT; Oliveira J; Jerónimo C; Henrique R
Urol Oncol; 2018 Apr; 36(4):161.e7-161.e17. PubMed ID: 29174711
[TBL] [Abstract][Full Text] [Related]
13. PSA doubling time as a predictor of clinical progression after biochemical failure following radical prostatectomy for prostate cancer.
Roberts SG; Blute ML; Bergstralh EJ; Slezak JM; Zincke H
Mayo Clin Proc; 2001 Jun; 76(6):576-81. PubMed ID: 11393495
[TBL] [Abstract][Full Text] [Related]
14. Outcomes of Gleason score 3 + 4 = 7 prostate cancer with minimal amounts (<6%) vs ≥6% of Gleason pattern 4 tissue in needle biopsy specimens.
Kır G; Seneldir H; Gumus E
Ann Diagn Pathol; 2016 Feb; 20():48-51. PubMed ID: 26750655
[TBL] [Abstract][Full Text] [Related]
15. Tumour growth fraction measured by immunohistochemical staining of Ki67 is an independent prognostic factor in preoperative prostate biopsies with small-volume or low-grade prostate cancer.
Zellweger T; Günther S; Zlobec I; Savic S; Sauter G; Moch H; Mattarelli G; Eichenberger T; Curschellas E; Rüfenacht H; Bachmann A; Gasser TC; Mihatsch MJ; Bubendorf L
Int J Cancer; 2009 May; 124(9):2116-23. PubMed ID: 19117060
[TBL] [Abstract][Full Text] [Related]
16. Percent of prostate needle biopsy cores with cancer is significant independent predictor of prostate specific antigen recurrence following radical prostatectomy: results from SEARCH database.
Freedland SJ; Aronson WJ; Terris MK; Kane CJ; Amling CL; Dorey F; Presti JC;
J Urol; 2003 Jun; 169(6):2136-41. PubMed ID: 12771735
[TBL] [Abstract][Full Text] [Related]
17. Significance of preoperative butyrylcholinesterase as an independent predictor of biochemical recurrence-free survival in patients with prostate cancer treated with radical prostatectomy.
Koie T; Ohyama C; Hatakeyama S; Imai A; Yoneyama T; Hashimoto Y; Yoneyama T; Tobisawa Y; Hosogoe S; Yamamoto H; Kitayama M; Hirota K
Int J Clin Oncol; 2016 Apr; 21(2):379-383. PubMed ID: 26223693
[TBL] [Abstract][Full Text] [Related]
18. Impact of the EpCAM expression on biochemical recurrence-free survival in clinically localized prostate cancer.
Benko G; Spajić B; Krušlin B; Tomas D
Urol Oncol; 2013 May; 31(4):468-74. PubMed ID: 21514185
[TBL] [Abstract][Full Text] [Related]
19. Prostate cancer outcomes of men with biopsy Gleason score 6 and 7 without cribriform or intraductal carcinoma.
Kweldam CF; Kümmerlin IP; Nieboer D; Verhoef EI; Steyerberg EW; Incrocci L; Bangma CH; van der Kwast TH; Roobol MJ; van Leenders GJ
Eur J Cancer; 2016 Oct; 66():26-33. PubMed ID: 27522247
[TBL] [Abstract][Full Text] [Related]
20. Prognostic Significance for Long-Term Outcomes Following Radical Prostatectomy in Men with Prostate Cancer: Evaluation with Prostate Imaging Reporting and Data System Version 2.
Kim R; Kim CK; Park JJ; Kim JH; Seo SI; Jeon SS; Lee HM
Korean J Radiol; 2019 Feb; 20(2):256-264. PubMed ID: 30672165
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
